Phase II clinical studies conducted on 46 CLL patients concluded that while anti-VEGF therapy, including avastin, remains a viable therapy for CLL, using a single agent anti-VEGF monotherapy had limited activity in CLL patients, and combination therapy is a more feasible approach particularly for patients with relapsed/refractory CLL (61). Here, VEGFA is linked to B-cell chronic lymphocytic leukemia.